United Therapeutics Corp (UTHR)
237.00
+2.53
(+1.08%)
USD |
NASDAQ |
Apr 24, 16:00
240.00
+3.00
(+1.27%)
Pre-Market: 08:31
United Therapeutics Enterprise Value: 8.859B for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 8.859B |
| April 23, 2024 | 8.740B |
| April 22, 2024 | 8.720B |
| April 19, 2024 | 8.903B |
| April 18, 2024 | 8.855B |
| April 17, 2024 | 8.779B |
| April 16, 2024 | 8.613B |
| April 15, 2024 | 8.768B |
| April 12, 2024 | 8.651B |
| April 11, 2024 | 8.870B |
| April 10, 2024 | 8.896B |
| April 09, 2024 | 8.861B |
| April 08, 2024 | 8.857B |
| April 05, 2024 | 8.697B |
| April 04, 2024 | 8.714B |
| April 03, 2024 | 8.586B |
| April 02, 2024 | 8.463B |
| April 01, 2024 | 8.447B |
| March 28, 2024 | 8.516B |
| March 27, 2024 | 9.154B |
| March 26, 2024 | 9.370B |
| March 25, 2024 | 9.200B |
| March 22, 2024 | 8.901B |
| March 21, 2024 | 8.855B |
| March 20, 2024 | 8.846B |
| Date | Value |
|---|---|
| March 19, 2024 | 8.972B |
| March 18, 2024 | 8.716B |
| March 15, 2024 | 8.801B |
| March 14, 2024 | 8.911B |
| March 13, 2024 | 9.060B |
| March 12, 2024 | 9.323B |
| March 11, 2024 | 9.447B |
| March 08, 2024 | 9.143B |
| March 07, 2024 | 8.998B |
| March 06, 2024 | 8.857B |
| March 05, 2024 | 8.520B |
| March 04, 2024 | 8.470B |
| March 01, 2024 | 8.620B |
| February 29, 2024 | 8.324B |
| February 28, 2024 | 8.401B |
| February 27, 2024 | 8.376B |
| February 26, 2024 | 8.227B |
| February 23, 2024 | 8.390B |
| February 22, 2024 | 7.946B |
| February 21, 2024 | 8.020B |
| February 20, 2024 | 7.784B |
| February 16, 2024 | 7.811B |
| February 15, 2024 | 7.802B |
| February 14, 2024 | 7.797B |
| February 13, 2024 | 7.761B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.554B
Minimum
Jul 22 2019
10.97B
Maximum
Dec 09 2022
6.710B
Average
7.518B
Median
May 24 2021
Enterprise Value Benchmarks
| Liquidia Corp | 870.47M |
| Esperion Therapeutics Inc | 573.51M |
| Vertex Pharmaceuticals Inc | 92.30B |
| Heron Therapeutics Inc | 491.71M |
| Aldeyra Therapeutics Inc | 104.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 217.10M |
| Revenue (Quarterly) | 614.70M |
| Total Expenses (Quarterly) | 354.60M |
| EPS Diluted (Quarterly) | 4.36 |
| Gross Profit Margin (Quarterly) | 88.45% |
| Profit Margin (Quarterly) | 35.32% |
| Earnings Yield | 8.37% |
| Operating Earnings Yield | 10.06% |
| Normalized Earnings Yield | 8.371 |